At the end of 2008, the experts of American Col lege of Cardiology Foundation (ACCF), American Heart Association (AHA), and American College of Gastroenterology (ACG) published a joint po sition statement which encompassed the recom mendations for reduction in gastrointestinal com plications, particularly gastrointestinal hemo rrhage, in patients on antiplatelet therapy. 1 Since no such document has been prepared by the Euro pean institutions, knowledge of the above recom mendations appears highly important. Therefore, the members of the ad hoc Polish Working Group advise that the recommendations should be dis seminated and implemented in Poland.
Numerous observations have confirmed the presence of patient groups at high risk of gas trointestinal complications during antiplatelet treatment. The major risk factor is a history of peptic ulcer disease, particularly with bleeding complications. The risk of gastrointestinal compli cations also increases with age, especially in sub jects aged >60 years. It is also higher in patients with a prior history of bleeding from other sites than the gastrointestinal tract, in women, in pa tients with concomitant renal insufficiency, in pa tients on glucocorticosteroids and nonsteroidal antiinflammatory drugs, and in patients with dyspepsia or symptoms of gastroesophageal reflux disease. Complications occur far more frequent ly during combined therapy with an antiplatelet agent and an anticoagulant. It refers mostly to pa tients on intensive antiplatelet and anticoagulant therapy, including those with an acute coronary syndrome. Therefore, it is necessary that special ists in inter nal diseases, gastroenterology, and cardiology adopt a joint strategy to prevent gas trointestinal bleeding complications.
In most patients who are treated with acetyl salicylic acid (ASA) for the prevention of cardio vascular events, low doses of this drug should be administered. It has been demonstrated that 75-160 mg daily doses of ASA were as effective as higher doses. No further decrease in the risk of cardiovascular events was observed at higher doses of ASA, although there was a significant increase in complication rate. Therefore, the rou tine ASA administration of 75 mg/day for car diovascular indications should be recommend ed. Proton pump inhibitors (PPIs) are the only recommended class of drugs with proven effica cy in the prevention of gastrointestinal complica tions. Easy dosage (once a day) and an extremely low rate of adverse effects contributed to wide spread use of PPIs. The efficacy of PPIs has been shown in multiple studies designed to evaluate gastroscopic lesions and the incidence of gastro intestinal bleedings.
In a joint document, ACCF/AHA and ACG pub lished an outline algorithm to prevent gastroin testinal complications in patients receiving anti platelet therapy (FIGURE). The experts make pro phylactic treatment dependent on the presence of risk factors. 3 Preventive PPI administration should be continued as long as the risk factor specified in the FIGURE is present (e.g. PPI administra tion in patients with acute coronary syndrome is continued for the duration of the combined treatment with ASA and clopidogrel). 4 Esomeprazole and pantoprazole are preferred PPIs in patients treated with clopidogrel while other PPIs, particularly omeprazole, are not rec ommended due to a risk of significant inter actions with clopidogrel.
Notice This position paper has been submit ted to a number of Polish journals of inter nal diseases, gastroenterology and cardiology with a request for publication. It is also available on the websites of National Consultants in the ap propriate disciplines. Jacek Imiela is the National Consultant in In ternal Diseases, Grzegorz Opolski is the National Consultant in Cardiology, and Grażyna Rydzewska is the National Consultant in Gastroenterology. a prior history of peptic ulcer; in patients with gastrointestinal bleeding; in patients on double antiplatelet treatment; and in those receiving oral anticoagulant therapy. Moreover, patients with a prior history of peptic ulcer should be tested for Helicobacter pylori (provided that they have not undergone the test previously), and if the test is positive an eradication treatment should be ad ministered. Efficacy of eradication treatment is not an indication for PPI discontinuation. PPI ad ministration as a preventive measure is recom mended in patients with at least two of the fol lowing risk factors: age ≥60 years, glucocorti costeroid therapy, signs or symptoms of dyspep sia or gastroesophageal reflux disease.
The choice of a specific PPI for the above indi cations is a significant therapeutic challenge. Re cently, a series of reports have been published showing that omeprazole and other PPIs decrease antiplatelet effect of clopidogrel. No such effects have been reported with regard to esomepra zole and pantoprazole. This is most often linked with competitive meta bolism of some PPIs and clopidogrel mediated by cytochrome P450 2C19 (CYP2C19) isoenzyme and possibly by other iso forms of this cytochrome. [2] [3] [4] [5] [6] [7] In light of the above reports and results of the latest clinical trials, the Polish Working Group presents the recommendations as listed below. 1 In patients who are treated with ASA, PPIs should be administered in the case of: 
